March 31, 2008 – Transave Inc. reported today that its lead product candidate, ARIKACE™ (liposomal amikacin for inhalation), may have the ability to penetrate mucus and biofilms, and decrease the number of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis, according to results of a study published in the Journal of Antimicrobial Chemotherapy. Results of the study titled "Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomanas aeruginosa lung infections," were published in the April issue of the journal. Transave is a biopharmaceutical company focused on the development of next-generation liposomal drug products for inhalation.
ARIKACE is a form of the antibiotic amikacin, which is enclosed in nanocapsules of lipids called liposomes... Transave's Press Release -
